The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Platelet Count

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Platelet Count

 

Psychiatry related information on Platelet Count

 

High impact information on Platelet Count

  • CR3-expressing but not CR3-deficient mice exposed to cold rapidly decrease platelet counts [8].
  • The patients had to have a leukocyte count of at least 3000 per cubic millimeter, a platelet count of at least 100,000 per cubic millimeter, a serum creatinine level no higher than 2 mg per deciliter (177 micromol per liter), and adequate hepatic function [9].
  • RESULTS: In the 38 patients who received MGDF after chemotherapy, the median nadir platelet count was 188,000 per cubic millimeter (range, 68,000 to 373,000), as compared with 111,000 per cubic millimeter (range, 21,000 to 307,000) in 12 patients receiving placebo (P = 0.013) [10].
  • With the higher dose of azathioprine, four patients had myelosuppression, defined as a decrease in the leukocyte and platelet counts to less than 4000 and 150,000 per cubic millimeter, respectively [11].
  • The median platelet count at the start of 2-chlorodeoxyadenosine therapy in these 10 patients was 24,000 per cubic millimeter, as compared with 109,000 per cubic millimeter in the other 18 patients [12].
 

Chemical compound and disease context of Platelet Count

 

Biological context of Platelet Count

 

Anatomical context of Platelet Count

  • CONCLUSIONS: These results show that the magnitude of MGMT depletion by STZ in PBMC is in the range necessary to produce sensitivity to CENUs in resistant cell lines but also that, when BCNU is combined with STZ, the MTD of BCNU is about 50% that of BCNU as a single agent and that platelet count suppression occurs earlier [23].
  • Abnormal laboratory findings included a low lymphocyte count (nine patients), low platelet count, low serum sodium, and high aspartate aminostransferase concentration (each observed in five patients) [24].
  • The intention was to administer IFN as soon as stable engraftment after BMT was achieved (defined as an absolute neutrophil count of greater than 2.0 x 10(9)/L and platelet count greater than 100 x 10(9)/L for 5 consecutive days) and continued for 2 months [25].
  • The normalization of circulating platelet numbers in carboplatin plus MGDF-treated mice is accompanied by a normalization of megakaryocyte numbers in the bone marrow [26].
  • This treatment raised their platelet count and simultaneously decreased the ability of their granulocytes to phagocytize antibody-coated platelets and C3-coated paraffin oil droplets [27].
 

Associations of Platelet Count with chemical compounds

  • We also tested a representative subgroup of 387 patients for heparin-dependent IgG antibodies regardless of their platelet counts [28].
  • Eleven of 12 patients (92 percent) responded to prednisone with a mean threefold increase in the platelet count, resulting from increased platelet production (P less than 0.005); platelet survival was unchanged [29].
  • The presence of concomitant medical problems, a low platelet count, a high serum urea nitrogen concentration, and a low serum albumin concentration before biliary decompression were the other independent determinants of mortality in both groups [30].
  • The acute effects of intravenous somatostatin (0.8 micrograms per kilogram per minute for two hours) in previously untreated animals transiently decreased platelet count, reduced retention of platelets on glass-bead columns and inhibited aggregation induced by ADP, collagen and epinephrine [31].
  • Mean platelet survival was also significantly decreased in the HIV-infected patients with normal platelet counts (untreated, 162 +/- 23 hours, P < 0.01; zidovudine-treated, 166 +/- 35 hours, P < 0.05) [32].
 

Gene context of Platelet Count

  • An inverse correlation between activated VWF levels and platelet count was observed (R2 = 0.74; P < .003) [33].
  • No definitive association was found between the continuous high levels of G-CSF and infective episodes, the number of infused nucleated cells, monocytes, CFU-GM, or the number of days required to achieve greater than 0.5 x 10(9)/L granulocyte, greater than 1.0 x 10(9)/L leukocyte, or greater than 50 x 10(9)/L platelet counts [34].
  • Treatment of mice with purified recombinant Tpo increases platelet count fourfold and expands colony-forming unit-megakaryocyte (CFU-Meg) numbers [35].
  • Median peak platelet counts were, respectively, 511 x 10(9)/L (range, 384 to 694 x 10(9)/L) and 579 x 10(9)/L (range, 526 to 910 x 10(9)/L) in patients with tumors producing G-CSF and GM-CSF [36].
  • However, consistent with a potential role in vivo, when injected into mpl-/- mice, interleukin-6 (IL-6) and leukemia inhibitory factor (LIF) retained the capacity to elevate megakaryocytes and their progenitors in hematopoietic tissues and increase circulating platelet numbers [37].
 

Analytical, diagnostic and therapeutic context of Platelet Count

References

  1. Temporal aspects of heparin-induced thrombocytopenia. Warkentin, T.E., Kelton, J.G. N. Engl. J. Med. (2001) [Pubmed]
  2. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., Barbui, T. N. Engl. J. Med. (1995) [Pubmed]
  3. Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. Gardner, F.H., Helmer, R.E. JAMA (1980) [Pubmed]
  4. Heparin-associated thrombosis despite normal platelet counts. Hach-Wunderle, V., Kainer, K., Krug, B., Müller-Berghaus, G., Pötzsch, B. Lancet (1994) [Pubmed]
  5. Common epitope on HIV p24 and human platelets. Hohmann, A.W., Booth, K., Peters, V., Gordon, D.L., Comacchio, R.M. Lancet (1993) [Pubmed]
  6. Gender differences in platelet count and its association with cigarette smoking in a large cohort in Israel. Green, M.S., Peled, I., Najenson, T. Journal of clinical epidemiology. (1992) [Pubmed]
  7. Serotonin metabolism in cystic fibrosis. Partington, M.W., Ferguson, A.C. Arch. Dis. Child. (1977) [Pubmed]
  8. The clearance mechanism of chilled blood platelets. Hoffmeister, K.M., Felbinger, T.W., Falet, H., Denis, C.V., Bergmeier, W., Mayadas, T.N., von Andrian, U.H., Wagner, D.D., Stossel, T.P., Hartwig, J.H. Cell (2003) [Pubmed]
  9. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. Rose, P.G., Bundy, B.N., Watkins, E.B., Thigpen, J.T., Deppe, G., Maiman, M.A., Clarke-Pearson, D.L., Insalaco, S. N. Engl. J. Med. (1999) [Pubmed]
  10. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. Fanucchi, M., Glaspy, J., Crawford, J., Garst, J., Figlin, R., Sheridan, W., Menchaca, D., Tomita, D., Ozer, H., Harker, L. N. Engl. J. Med. (1997) [Pubmed]
  11. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. Johnson, P.J., McFarlane, I.G., Williams, R. N. Engl. J. Med. (1995) [Pubmed]
  12. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. O'Brien, S., Kantarjian, H., Estey, E., Koller, C., Robertson, B., Beran, M., Andreeff, M., Pierce, S., Keating, M. N. Engl. J. Med. (1994) [Pubmed]
  13. Treatment of human immunodeficiency virus-related thrombocytopenia with zidovudine. Pottage, J.C., Benson, C.A., Spear, J.B., Landay, A.L., Kessler, H.A. JAMA (1988) [Pubmed]
  14. Serum factors releasing serotonin from normal platelets: relation to the manifestations of systemic lupus erythematosus. Ginsberg, M.H., O'Malley, M. Ann. Intern. Med. (1977) [Pubmed]
  15. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Bennett, C.L., Weinberg, P.D., Rozenberg-Ben-Dror, K., Yarnold, P.R., Kwaan, H.C., Green, D. Ann. Intern. Med. (1998) [Pubmed]
  16. Immune thrombocytopenia in lymphoproliferative diseases. Kaden, B.R., Rosse, W.F., Hauch, T.W. Blood (1979) [Pubmed]
  17. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha 2b interferon. Proctor, S.J., Jackson, G., Carey, P., Stark, A., Finney, R., Saunders, P., Summerfield, G., Maharaj, D., Youart, A. Blood (1989) [Pubmed]
  18. The usefulness of preoperative laboratory screening. Kaplan, E.B., Sheiner, L.B., Boeckmann, A.J., Roizen, M.F., Beal, S.L., Cohen, S.N., Nicoll, C.D. JAMA (1985) [Pubmed]
  19. Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys. Colucci, M., Stassen, J.M., Collen, D. J. Clin. Invest. (1984) [Pubmed]
  20. Coagulopathy during ascites reinfusion: prevention by antiplatelet therapy. Tang, H.H., Salem, H.H., Wood, L.J., Dudley, F.J. Gastroenterology (1992) [Pubmed]
  21. Erythroid Krüppel-like factor (EKLF) is active in primitive and definitive erythroid cells and is required for the function of 5'HS3 of the beta-globin locus control region. Tewari, R., Gillemans, N., Wijgerde, M., Nuez, B., von Lindern, M., Grosveld, F., Philipsen, S. EMBO J. (1998) [Pubmed]
  22. Platelet function, thromboxane formation and blood pressure control during supplementation of the Western diet with cod liver oil. Lorenz, R., Spengler, U., Fischer, S., Duhm, J., Weber, P.C. Circulation (1983) [Pubmed]
  23. Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. Micetich, K.C., Futscher, B., Koch, D., Fisher, R.I., Erickson, L.C. J. Natl. Cancer Inst. (1992) [Pubmed]
  24. Outbreak of Nipah-virus infection among abattoir workers in Singapore. Paton, N.I., Leo, Y.S., Zaki, S.R., Auchus, A.P., Lee, K.E., Ling, A.E., Chew, S.K., Ang, B., Rollin, P.E., Umapathi, T., Sng, I., Lee, C.C., Lim, E., Ksiazek, T.G. Lancet (1999) [Pubmed]
  25. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. Klingemann, H.G., Grigg, A.P., Wilkie-Boyd, K., Barnett, M.J., Eaves, A.C., Reece, D.E., Shepherd, J.D., Phillips, G.L. Blood (1991) [Pubmed]
  26. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Ulich, T.R., del Castillo, J., Yin, S., Swift, S., Padilla, D., Senaldi, G., Bennett, L., Shutter, J., Bogenberger, J., Sun, D. Blood (1995) [Pubmed]
  27. Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Handin, R.I., Stossel, T.P. Blood (1978) [Pubmed]
  28. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. Warkentin, T.E., Levine, M.N., Hirsh, J., Horsewood, P., Roberts, R.S., Gent, M., Kelton, J.G. N. Engl. J. Med. (1995) [Pubmed]
  29. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. Gernsheimer, T., Stratton, J., Ballem, P.J., Slichter, S.J. N. Engl. J. Med. (1989) [Pubmed]
  30. Endoscopic biliary drainage for severe acute cholangitis. Lai, E.C., Mok, F.P., Tan, E.S., Lo, C.M., Fan, S.T., You, K.T., Wong, J. N. Engl. J. Med. (1992) [Pubmed]
  31. Effects of somatostatin on hemostasis in baboons. Koerker, D.J., Harker, L.A., Goodner, C.J. N. Engl. J. Med. (1975) [Pubmed]
  32. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. Ballem, P.J., Belzberg, A., Devine, D.V., Lyster, D., Spruston, B., Chambers, H., Doubroff, P., Mikulash, K. N. Engl. J. Med. (1992) [Pubmed]
  33. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Hulstein, J.J., de Groot, P.G., Silence, K., Veyradier, A., Fijnheer, R., Lenting, P.J. Blood (2005) [Pubmed]
  34. Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts. Kawano, Y., Takaue, Y., Saito, S., Sato, J., Shimizu, T., Suzue, T., Hirao, A., Okamoto, Y., Abe, T., Watanabe, T. Blood (1993) [Pubmed]
  35. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Broudy, V.C., Lin, N.L., Kaushansky, K. Blood (1995) [Pubmed]
  36. Thrombocytosis in patients with tumors producing colony-stimulating factor. Suzuki, A., Takahashi, T., Nakamura, K., Tsuyuoka, R., Okuno, Y., Enomoto, T., Fukumoto, M., Imura, H. Blood (1992) [Pubmed]
  37. Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production. Gainsford, T., Roberts, A.W., Kimura, S., Metcalf, D., Dranoff, G., Mulligan, R.C., Begley, C.G., Robb, L., Alexander, W.S. Blood (1998) [Pubmed]
  38. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Despotis, G.J., Levine, V., Saleem, R., Spitznagel, E., Joist, J.H. Lancet (1999) [Pubmed]
  39. Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding. Uthoff, K., Zehr, K.J., Geerling, R., Herskowitz, A., Cameron, D.E., Reitz, B.A. Circulation (1994) [Pubmed]
  40. Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass. Davies, G.C., Sobel, M., Salzman, E.W. Circulation (1980) [Pubmed]
  41. Protection of platelets during long-term extracorporeal membrane oxygenation in sheep with a single dose of a disintegrin. Shigeta, O., Gluszko, P., Downing, S.W., Lu, W., Niewiarowski, S., Edmunds, L.H. Circulation (1992) [Pubmed]
 
WikiGenes - Universities